RE:RE:AstraZeneca paid USD$ 5.5 Billion to co-market Enhertu August 04, 2022 - AstraZeneca is working on ' off-the-self ' (allogeneic) CAR-T therapy with the intent of targeting solid tumors, according to Dave Fredrickson, executive vice president of AstraZeneca's oncology business unit.
"Targeting CAR-Ts in solid tumors is a widely held ambition among Big Pharma"
ONCY has already demonstrated the curative effect of CAR-T therapy + pelareorep + pelareorep "boost" in the treatment of solid tumors.
https://www.fiercebiotech.com/biotech/late-car-t-game-astrazeneca-quietly-working-its-own-shelf-options